Ubs Asset Management Americas Inc Immuno Gen, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $59,421 - $142,831	4,769 Added 1.56%	310,789 $9.21 Million
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $172,320 - $243,010	12,230 Added 4.16%	306,020 $4.86 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $171,429 - $229,818	46,711 Added 18.91%	293,790 $1.13 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $11,270 - $15,629	2,477 Added 1.01%	247,079 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $111,256 - $160,675	24,834 Added 11.3%	244,602 $1.17 Million
Q2 2022 Aug 12, 2022	BUY	$3.15 - $5.76 $102,822 - $188,017	32,642 Added 17.44%	219,768 $988,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $128,216 - $202,447	26,993 Added 16.86%	187,126 $1.39 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $14,317 - $18,794	2,852 Added 1.81%	160,133 $907,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $68,819 - $102,219	11,886 Added 8.17%	157,281 $1.04 Million
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $106,931 - $173,229	-16,451 Reduced 10.16%	145,395 $1.18 Million
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $38,548 - $62,002	11,611 Added 7.73%	161,846 $744,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $79,629 - $255,414	-37,561 Reduced 20.0%	150,235 $512,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $85,581 - $220,608	38,036 Added 25.4%	187,796 $959,000
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $38,938 - $59,460	17,540 Added 13.27%	149,760 $362,000
Q1 2019 May 14, 2019	BUY	$2.41 - $5.91 $51,065 - $125,226	21,189 Added 19.08%	132,220 $0
Q4 2018 Feb 13, 2019	BUY	$3.94 - $9.7 $66,274 - $163,163	16,821 Added 17.85%	111,031 $532,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $40,420 - $52,922	4,700 Added 5.25%	94,210 $0
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $65,688 - $83,835	6,900 Added 8.35%	89,510 $0
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $251,960 - $486,997	37,606 Added 83.56%	82,610 $0
Q4 2017 Feb 09, 2018	SELL	$5.07 - $7.92 $26,541 - $41,461	-5,235 Reduced 10.42%	45,004 $0
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $271,290 - $425,524	50,239	50,239 $0

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account